Skip to main content
D&D Pharmatech Inc. logo

D&D Pharmatech Inc. — Investor Relations & Filings

Ticker · 347850 ISIN · KR7347850000 KO Manufacturing
Open in API
Filings indexed 109 across all filing types
Latest filing 2025-03-20 Audit Report / Informat…
Country KR South Korea
Listing KO 347850

About D&D Pharmatech Inc.

http://www.ddpharmatech.com/

D&D Pharmatech is a clinical-stage biopharmaceutical company specializing in the development of therapies based on GLP-1 (Glucagon-like peptide-1) and related peptides. The company's pipeline primarily targets metabolic diseases, including obesity and MASH (Metabolic dysfunction-associated steatohepatitis), as well as neurodegenerative disorders. A core competency is its proprietary oral peptide delivery technology. Key candidates in its portfolio include DD01, an injectable dual GLP-1/glucagon receptor agonist for MASH that has received FDA Fast Track Designation, and an oral GLP-1 therapy for obesity. The company operates a global model, funding drug development through specialized subsidiaries, with research functions in Korea and clinical development managed by its US-based team.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed with the Korea Exchange (KRX). It provides the auditor's opinion (unqualified/appropriate), key financial data (assets, liabilities, equity, profit/loss), and specific regulatory disclosures required for listed companies in Korea. While it contains financial data, it is a regulatory filing announcing the receipt and submission of the audit report rather than the full 10-K annual report document itself. Therefore, it is classified as a Regulatory Filing. FY 2024
2025-03-20 Korean
사업보고서 (2024.12)
Annual Report Classification · 1% confidence The document is titled '사업보고서' (Business Report) for '주식회사 디앤디파마텍' (D&D Pharmatech Inc.) for the fiscal year 2024 (Jan 1, 2024 to Dec 31, 2024). It contains detailed sections on company overview, history, management, capital structure, and business operations, which are characteristic of a comprehensive annual report filed with regulatory bodies (Financial Services Commission and Korea Exchange). It is not a short announcement or a certification, but the full report itself. FY 2024
2025-03-20 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 1% confidence The document is a formal announcement regarding an upcoming 'Corporate Presentation' (IR event) scheduled by D&D Pharmatech. It provides details such as the date, location, purpose (clinical trial updates), and method (Non-Deal Roadshow). Since this is an announcement of an event rather than the presentation slides themselves, and it serves as a regulatory notification of corporate activity, it fits best under the 'Regulatory Filings' category as it is a standard disclosure of an IR event schedule.
2025-03-19 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 1% confidence The document is a formal announcement regarding an upcoming 'Corporate Presentation' (IR event) scheduled for March 24, 2025. It details the date, location, purpose (clinical trial updates), and method (Non-Deal Roadshow). Since this is an announcement of an event and the availability of materials rather than the presentation slides themselves, it falls under the category of a regulatory announcement regarding corporate activities.
2025-03-13 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for D&D Pharmatech. It contains the meeting agenda, details on voting procedures, director activity reports, and financial statements (balance sheet, income statement) for the 11th fiscal year. This type of document is standard for proxy solicitation and shareholder information provided ahead of an AGM, which falls under the 'Proxy Solicitation & Information Statement' category.
2025-03-13 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (Proxy Solicitation & Information Statement). It contains information regarding the upcoming Annual General Meeting (AGM), including the purpose of the meeting, details on the proxy solicitation, and financial statements (balance sheets, income statements, etc.) provided as reference materials for shareholders to exercise their voting rights. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2025-03-13 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.